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Abstract
Inflammatory cells are involved in tumour initiation and progression. In parallel, the adaptive immune response plays a key role in fighting
tumour growth and dissemination. The double-edged role of the immune system in solid tumours is well represented in colorectal cancer
(CRC). The development and progression of CRC are affected by the interactions between the tumour and the host’s response, occurring in a
milieu named tumour microenvironment. The role of immune cells in human CRC is being unravelled and there is a strong interest in under-
standing their dynamics as to tumour promotion, immunosurveillance and immunoevasion. A better definition of immune infiltration would be
important not only with respect to the ‘natural history’ of CRC, but in a clinically relevant perspective in the 21st century, with respect to its
post-surgical management, including chemotherapy responsiveness. While it is becoming established that the amount of tumour-infiltrating
lymphocytes influences the post-surgical progression of early-stage CRC, the relevance of this immune parameter as to chemotherapy respon-
siveness remains to be clarified. Despite recent experimental work supporting the notion that infiltrating immune cells may influence chemo-
therapy-mediated tumour cell death, tumour-infiltrating cells are not employed to identify patients who are more likely to benefit from adjuvant
treatment. This review focuses on studies addressing the role of innate and adaptive immune cells along the occurrence and the progression of
potentially curable CRC.
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Colorectal cancer: epidemiology and staging
In 2008, IARC ranked colorectal cancer (CRC) second for cancer
prevalence and third for mortality in men and third for frequency
and second for mortality in women in developed countries.
Advances in population screening strategies make possible an early
detection of precancerous lesions. Accordingly, data from the Sur-
veillance, Epidemiology, and End Results (SEER) program of the NCI
(National Cancer Institute of the United States) on a population
screened from 1998 to 2008 revealed a decrease in CRC incidence
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(2.6%, 2.0%; for men and women respectively) and a decrease
in CRC-related mortality (2.3%, 2.1%) [1]. However, regardless
of improved screening, surgical technique and adjuvant CHT, nearly
a third of CRC patients experience disease recurrence. About 20–
25% of patients with CRC have metastases at diagnosis, and 20–
25% of patients will develop metachronous metastases after
surgery, resulting in relatively high overall mortality rates [2]. In syn-
thesis, CRC death parallels the incidence of metastatic disease, and
in 2008, CRC was still the cause of 9% of overall cancer-related
deaths in US. Surgery still represents the backbone of CRC treat-
ment, retaining the highest effect on survival. Following curative rad-
ical surgery in patients without lymph node or distant metastasis at
diagnosis, occult micro-metastases not detectable with the current
diagnostic tools are thought to be the source of disease recurrence
[3]. Cancer is not a single-disease entity, and the anatomical classifi-
cation based on the tissue or organ where it arises was the first
advance from considering all cancers as a uniform disease [4–7].
Tumour-node-metastasis (TNM) classification and staging system is
conceived to allow clinical stratification of patients according to the
estimated survival, to predict prognoses, to select the most effective
treatments and to allocate patients to chemotherapy [6]. To date,
the most relevant prognostic factor for CRC survival and recurrence
is the presence of tumour cells in regional lymph nodes at histopath-
ological examination, which identifies stage III patients [3]. However,
histopathological staging lacks accuracy, as it is based on a deter-
ministic prediction, and for this reason, an important percentage of
patients at greatest risk of disease recurrence are still undetected.
Accordingly, about 30% of stage II CRC patients will experience dis-
ease recurrence, while stage III patients after radical surgery, which
is thought to eradicate also cancer metastasized to regional lymph
nodes, exhibit recurrence rates of up to 70% [3]. Differences in CRC
recurrence among studies are likely an effect of down-staging of
CRC with stage III or IV respectively, because of misidentification of
cancer cells, an event named ‘Will Rogers’ effect [8]. Inaccuracy in
identifying CRC patients at risk reflects at least in part methodologi-
cal weakness in diagnostic procedures [3, 9, 10]. Imaging tech-
niques for pathological diagnosis still rely on the detection of
macroscopic tumour lesions, overlooking micrometastasis that
results later in metachronous metastasis, although few experimental
data are available to date on this issue. Conceptually, the limited
accuracy of traditional TNM staging system in predicting outcome
lies in the estimation of tumour progression as a merely linear pro-
cess, without taking into consideration the complexity of cancer evo-
lution as a balance of intrinsic and extrinsic determinants. To move
to a more personalized cancer medicine, there is the need for molec-
ular classifications that are able to identify patients with specific
molecular patterns, progression rates and responsiveness to chemo-
therapy, with the aim of optimizing drug treatments. The opposing
effects of inflammatory and adaptive components of the immune
system in solid tumours are well represented in CRC, a tumour
strongly sustained by inflammatory mechanisms [11, 12] and
greatly infiltrated by adaptive cells with anti-tumour properties [13–
16]. In the next chapters, we aim to discuss the differing roles of
immune cells along the progression of curable CRC.
The immune system in cancer
Cancer-related inflammation
Rudolf Virchow, 150 years ago, was the first who described the pres-
ence of infiltrating leucocytes in tumours, theorizing that cancer
arises at chronic inflammation sites [17]. In support of this view,
chronic infections have been later described as linked to about 15–
20% of tumours [18, 19]. Hepatitis B and C viruses, Helicobacter
pylori, and papilloma virus are established risk factors for increased
prevalence of hepatocellular, gastric and cervical cancer respectively.
Moreover, smoking and obesity have been associated with an
increase of 20% and 30% of risk of cancer respectively [20], and
together with drinking alcohol can in turn cause an inflammatory sta-
tus in the lungs and liver, which is thought to support the onset of
cancer [21–23]. According to such data, inflammation has been rec-
ognized as an important factor in enhancing cancer occurrence and it
has been recently integrated as a new ‘hallmark of cancer’ [24]. Solid
cancers are structures resembling the organ from which they arise
and their occurrence and progression are modified by the behaviour
of immune cells recruited in the tumour microenvironment [17].
Accordingly, the crosstalk between tumour cells and their milieu is
crucial along cancer progression [12]. Inflammation can affect the
tumourigenesis by modulating a variety of processes, including cellu-
lar proliferation, rate of mutagenesis, inhibition of apoptosis and
angiogenesis. Soluble mediators, including inflammatory cytokines
and chemokines, play a crucial role in such processes [12]. Overall,
extensive experimental, epidemiological and clinical data suggest that
chronic inflammation is causally linked to cancer occurrence [25],
with colon cancer being one of the paradigms of the connection
between inflammation and cancer.
Cancer-related inflammation in colorectal cancer
In the gut, chronic inflammation has been found to be a risk factor for
CRC occurrence. Crohn’s disease and ulcerative colitis, two inflam-
matory bowel diseases (IBD), are both associated with an increased
risk to develop colitis-associated CRC (CAC). Ulcerative colitis
patients have an increased risk of developing CRC depending upon
the duration of active disease (2%, 8% and 18% after 10, 20,
30 years of active disease respectively) [26], and the relative risk of
developing CRC did not differ between patients with Crohn’s colitis
and with ulcerative colitis of similar severity [27]. The pathogenesis
of IBD seems to be related to an excessive stimulation of the immune
system directed towards antigens of the gut microbiota leading to
chronic inflammation [28]. General consensus exists on the view that
chronic inflammation of the colon increases the risk of developing
CRC. However, it is worth considering that CAC is expected to
account for less than 2% of all CRC [29]. Excluding IBDs, the role of
inflammation in sporadic CRC is rather vague from a clinical and an
experimental point of view [30]. The evidence for cytokine-regulated
tumour promotion comes from studies in a mouse model of CAC
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[31]. However, according to Terzic et al., similar mechanisms might
be involved in the connection between inflammation and sporadic
CRC [12]. Among the most important inflammatory mediators,
tumour necrosis factor (TNF)-a and interleukin (IL)-6 are drivers of
cancer-associated inflammation, by activating nuclear factors NFKB
and STAT3 and inducing PTGS2 (prostaglandin G/H synthase and
cyclooxygenase, also known as COX-2) [12, 23, 32]. Colorectal can-
cer cell-lines retain constitutive expression of NFKB and STAT3 tran-
scription factors, which are thought to be essential components of
inflammatory pathways [33, 34]. However, as no activating mutations
in NFKB or STAT3 have been detected to date in colorectal or colitis-
associated tumours, it is likely that signalling pathways of these
components are activated upstream of such transcription factors, or
alternatively that they are activated in a paracrine or autocrine fashion
[12]. These signalling pathways have the ability to induce an inflam-
matory network in the tumour microenvironment, which might result
in an influential role in tumour progression [23, 32]. In clinical stud-
ies, the most convincing association between inflammation and risk
of developing sporadic CRC comes from an old drug. Many robust
epidemiological studies, both observational and randomized-con-
trolled ones, have reported that the consistent intake of non-steroidal
anti-inflammatory drugs (NSAIDs) like aspirin is associated with a
lower probability of developing gastrointestinal cancer [35–38]. This
effect is supposed to be mediated through abrogation of chronic
inflammation. Non-steroidal anti-inflammatory drugs specifically tar-
get cyclooxygenases PTGS1 (prostaglandin G/H synthase and cyclo-
oxygenase, also known as COX-1) and PTGS2, which are essential
players in the induction of inflammatory pathways [39]. Accordingly,
many studies have shown that PTGS2 plays a significant role in can-
cer development by promoting inflammation and cell proliferation
[40]. In this regard, an epidemiological study from Chan, with a
cohort of more than 30 thousands women, showed that those with
very high plasma levels of TNFRSF1B protein had a higher risk of
CRC, and the chemo-protective effect of aspirin was retained only
among women with high TNFRSF1B protein levels [30]. This is an
associative evidence supporting the hypothesis that aspirin reduces
risk of colorectal neoplasia through inhibition of inflammatory path-
ways only in selected subgroups of patients. On the other hand, it is
important to underline that the effect of aspirin on the survival after
CRC diagnosis is still debated, raising doubts on aspirin use as an
agent for adjuvant therapy in CRC. Data from a recent paper from Liao
et al. show that regular aspirin use on patients after CRC diagnosis
had an impact on postsurgical survival only in the subgroup of
patients with PIK3CA (phosphatidylinositol-4, 5-bisphosphonate 3-
kinase catalytic subunit alpha gene) mutations in the tumour [41].
Mutations in PIK3CA are found in only about 15–20% of CRC [41,
42]. Therefore, NSAIDs’ protective effect in the progression of CRC
seems to be retained only among subclasses of patients with peculiar
molecular features, supporting a ‘tailored’ role of chronic inflamma-
tion in sporadic CRC pathogenesis, from onset up to its progression.
Overall, considering the heterogeneity of CRC behaviour among
patients and the complex interactions between tumour and immune
cells in cancer microenvironment, it is challenging to define the role
of immune cell types, cytokines or growth factors in promoting or
containing cancer. Thus, caution is required when assessing the con-
tribution of mediators of inflammation to cancer biology, as they
might reveal variable roles along tumour progression, even within the
same organ.
Anti-tumour activities of the immune system in
colorectal cancer
Besides chronic inflammation, which is thought to be critically
involved in tumour occurrence, experimental and clinical evidence
has revealed a protective role for immune cells along cancer pro-
gression. It was the possibility of developing new genetic models
of immunodeficiency that in the early 1990s readdressed the under-
standing of the roles of immunity in cancer. The idea that the
immune system controls tumour outgrowth, namely cancer immu-
nosurveillance, resides in the property of cancer cells to express
antigens that are not expressed by the normal tissue from which
they arise. Seminal experimental models indirectly demonstrated
the presence of tumour antigens, which were named ‘transplanta-
tion rejection antigens’ [43]. This evidence led to the assumption
that the immune system has a dual role on cancer evolution, elimi-
nating or promoting it. In 2002, Schreiber et al. postulated the
cancer immunoediting theory proposing three phases of immuno-
surveillance: elimination, equilibrium and escape [44]. In the elimi-
nation phase, adaptive and innate immune systems interact to
detect tumour antigens and to eliminate it. In the second phase,
the immune system and tumour cells get into an equilibrium,
wherein tumour immunosurveillance restrains, but does not com-
pletely eliminate a population of tumour cells in constant clonal
evolution, thus shaping tumour cells immunogenicity alike in a Dar-
winian selection process. More aggressive tumour clones are
selected through waves of adaptations necessary to evade innate
and adaptive immune defence [45], thus contributing to tumour
progression [46]. Significant variations occurring between murine
and human immune repertoire, the lack of experimental models
properly recapitulating CRC disease progression and the great
range of immune infiltration extent among human CRC with the
same histological features paved the way for several ‘natural exper-
iments’ based on epidemiological evidence. Human immunodefi-
ciency (i.e., AIDS) patients have a higher risk of colon, pancreas,
lung, kidney, head and neck and melanoma cancers [46], which is
a clinical evidence supporting the relevance of cancer immunosur-
veillance. Moreover, reports exist of patients receiving organ trans-
plantation and later developing tumours identical to those that
previously had affected the donor, who had been treated and recov-
ered [47]. A plausible explanation for this evidence is that tumour
cells were present in the donor, even though not clinically detect-
able, and were kept in a dormant state from donor’s immune sys-
tem during the equilibrium phase. The transplant of such cells in
an immunodepressed and na€ıve host gave the ability to cancer cells
to grow and become clinically evident. Although the detailed nature
of CRC-related antigens has yet to be determined, many clinical
studies related the varying extent of immune cells to the prognosis
of patients [13–15, 48–56]. However, most of these studies were
designed to demonstrate the independent association of immune
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markers with CRC relapse and survival by their histopathological
features. In contrast, a study from Koch et al. functionally verified
on CRC human tissues that activation and cytotoxic activity of
CD8+ TILs were tumour specific and responsive to MUC1 [57], a
tumour-associated antigen (TAA) expressed by most CRC as non-
self-antigen. In this study, the authors found higher percentage of
activated CTL CD8+ TILs in CRC tissues compared with their nor-
mal counterpart, and their activation, cytotoxic activity and reactiv-
ity were correlated with the presence of functional tumour specific
reactive T cells in the blood and bone marrow. Importantly, they
found that the proportion of activated TILs decreased significantly
along tumour stage (from stage II through stage III-IV), showing
functional decrease in immunosurveillance together with CRC pro-
gression, as depicted by histopathological staging [57]. Atreya
et al. proposed that the proportion of activated CD8+ TILs and their
cytolytic ability are central to mediating an effective anti-tumour
activity [58, 59]. Authors demonstrated that the expression of EO-
MES (eomesodermin), a T-box transcription factor, was inversely
correlated with the presence of lymph node metastasis at diagnosis
and that was crucial in controlling the production of perforin by
CD8+ CTLs and thus enhancing their cytotoxic activity [58, 59]
(Fig. 1). In line with this clinical evidence, a paper from Laghi et al.
showed a clinical phenomenon consistent with cancer immunoes-
cape theory along with the progression of CRC from stage II to
stage III [15]. In this study, CD3+ densities lost their prognostic
ability in CRC patients with nodal metastasis, while they were a
strong prognostic factor for occurrence of metachronous metasta-
sis in patients without lymph-nodal involvement at diagnosis. This
paper provides phenomenological and clinical evidence that the
progression of CRC across TNM stages parallels the need for
cancer cells to undergo immune evasion (Fig. 1). Under this
respect, cancer immunoediting theory fits with the clinical behav-
iour of sporadic CRC. Surgery usually removes macroscopically
detectable CRC burden by physical excision, while adjuvant chemo-
therapy is administered by assuming that it will kill circulating
tumour cells and micrometastasis. Such cells are not detectable by
conventional diagnostic methods and are likely in a dormant state,
while after a given time, they may give rise to metachronous
metastases, the main cause of death in CRC. Immune system
might keep micrometastasis in an equilibrium phase for many
years, and the clonal evolution of tumour cells gives rise to clones
retaining the ability to escape immune recognition and cause recur-
rence. In this setting, it is important to underline that adjuvant che-
motherapy gives a survival advantage only to stage III but not to
stage II CRC patients with or without poor prognostic features
[60]. On the other hand, stage IV CRC patients not receiving radical
surgical treatment, if any, undergo chemotherapy as palliative medi-
cation [61, 62]. Accordingly, when taking into account stage I to
stage III CRCs, chemotherapy seems to have a beneficial effect
only at later stage of disease, when tumour clones are likely to
have spread elsewhere. Thus, it is tempting to speculate that che-
motherapy seems to have an anti-tumour effect only at a stage of
disease when immunoescape mechanisms are more likely to occur,
selecting tumour clones not detectable by the immune system for
proper elimination (Fig. 1). In this view, it is also tempting to
hypothesize that chemotherapy might enhance the de novo expres-
sion of molecules that might restore tumour cell immunogenicity
and their recognition by immune system. It is important to notice
that despite clinical evidence, the biological bases of discrepancies
in terms of chemotherapy benefit along CRC progression are still
unknown. Moreover, to date, CRC antigenic profile has yet to be
described, and the lack of experimental models correctly reproduc-
ing CRC progression might explain at least in part our lack of
knowledge.
A B
Fig. 1 Immunological and histological fea-
tures and therapeutic efficacy of Stage II
versus Stage III colorectal cancer (CRCs).
(A) No cancer cells infiltration is detect-
able in stage II CRC draining mesenteric
lymph nodes. (B) Stage III CRCs have at
least one diagnosed metastatic mesenteric
lymph node derived from the primary
tumour.
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Immune cells and prediction of
responsiveness to chemotherapy in
colorectal cancer
Chemotherapy might have several impacts on the immune system.
Although chemotherapy may lead to clinically relevant myelosuppres-
sion [63], it might also induce immunogenic cell death, involving the
de novo expression of immunogenic neo-antigens on tumour cells,
thus boosting immune cells’ anti-tumour abilities [64–68]. In CRC,
many clinical studies depicted densities of infiltrating immune cells as
positive prognostic factors [13–15, 48–53]. However, very few stud-
ies assessed the predictive value of immune cells on the effectiveness
of chemotherapy in CRC and did not provide convincing data. The
need for biomarkers predictive of response to chemotherapy would
have extremely important clinical implications and although these are
required with great expectations, prudence should be applied when
they are proposed to the medical and scientific community. In the
study from Laghi, CD3+ cells density did not influence stage III
patient’s survival treated with fluorouracil adjuvant therapy [15]. In
contrast, three studies (Prall et al., Morris et al., and Halama et al.,
respectively) reported association between chemotherapy clinical
response and the extent of adaptive immune cells in CRC patient’s
prognosis [69–72] (Table 1). The first and the second study did not
report any effect modification of the predictive abilities of adaptive
immune cells by properly assessing their statistical interaction with
chemotherapy treatment [69, 72], while the latter lacked a control
group of untreated CRC patients [70, 71]. The estimation of prognos-
tic markers by using subgroup analyses requires careful examination
and proper design. Accordingly, a differential prognostic ability of a
marker in distinct subgroups of patients is not evidence that the prog-
nostic effect of the marker differs according to the variable which
identifies subgroups. To prove an effect modification of immune cells
on chemotherapy treatment in predicting prognosis, it should be indi-
cated whether an interaction between these two variables exists at
multivariate analysis [73]. The study by Morris showed that in an
adjusted analysis, stage III colon cancer patients with higher densities
of tumour-infiltrating lymphocytes were gaining a survival advantage
from adjuvant chemotherapy [69]. It should be noted that in this
study the assessment of lymphocyte density was obtained by
pathological assessment, and not by taking advantage of computer-
assisted image analysis. This technology has the advantage of
providing continuous quantification for immune cells, making data
informative, detailed and statistically relevant to quantify the proper
threshold values. Moreover, in the two studies from Morris and Prall
respectively, it is counterintuitive that 5-FU chemotherapy was signifi-
cantly associated with a better survival in both subgroups of patients
with low or high lymphocytes [69, 72]. The study from Halama analy-
sed immune infiltration and prognosis in stage IV CRC patients who
received palliative chemotherapy treatment [70, 71] (Table 1). It has
to be considered that the absence of a ‘control arm’ of chemotherapy
untreated patients impedes the assessment of any effect modification
of immune cells on chemotherapy responsiveness. This problem is
critical as cancer patients within the so-called ‘natural history’ sce-
nario of the disease are no longer seen in the 21st century, and pro-
spective randomized-controlled clinical studies necessary to address
such an issue are ethically unfeasible. In this study, immune infiltra-
tion at the border of hepatic metastases was predicting better progno-
sis among CRC patients who received palliative chemotherapy [70,
71]. Immune infiltrate in CRC of stage IV primary tumour at diagnosis
has been reported to be scarce [48], possibly reflecting immunoes-
cape [74] in patients with liver metastases and dismal prognosis. Sur-
gery of metastases in the liver is unlikely to be radical, thus being a
potential confounding factor in prognostic assessment of immune
cells. Microsatellite Instability (MSI) is a peculiar carcinogenesis path-
way of genomic instability occurring in about 10% of the overall pop-
ulation of CRC [75]. Clinically, MSI in CRC was shown to be a
molecular negative predictor of responsiveness to chemotherapy
treatment [76, 77], despite being characterized as having a much
higher extent of lymphocytic infiltration in the tumour stromal [15,
50, 51, 78] together with a lower metastatic potential at diagnosis
[75]. This evidence is counter-intuitive in the light of preclinical data
in CRC showing that chemotherapy positively interacts with adaptive
cells’ anti-tumour activities [64–68]. Ogino et al. pointed out that,
according to the intrinsic molecular heterogeneity existing also in
cancers with the same histopathological features, studies assessing
the prognostic impact of immune infiltration should take consider-
ation of relevant molecular features such as PIK3CA and MSI as
potential confounding factors [79]. The study from Dahlin et al. pro-
vided evidence that MSI prognostic advantage might be dependent on
the extent of CD3+ immune cells [80]. The interactions of these
important CRC features in the context of chemotherapy treatment and
stage of disease, however, remain to be uncovered. The low preva-
Table 1 Studies addressing the predictive abilities of immune cells in CRC patient’s responsiveness to chemotherapy treatment
Author (year) Ref.
No. of
patients
TNM
stage
Control arm*
Effect
modification
TILs markers TILs quantification
Halama (2011) [70] 101 IV No ND CD3+, CD8+, GZB+ or FOXP3+TILs Computer assisted
Laghi (2009) [15] 286 II-III Yes No effect CD3+TILs Computer assisted
Morris (2008) [69] 1156 III Yes ND None Semi-quantitative
Prall (2004) [72] 152 III Yes ND CD8+TILs Computer assisted
*CRC Patients not receiving adjuvant chemotherapy treatment.
ND: not determined; CRC: colorectal cancer.
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lence of molecular biomarkers is a critical issue and, as previously
suggested [79], future studies should be designed by taking advan-
tage of large cohorts of CRC patients and standardized methodolo-
gies. Thus, despite preclinical evidence, clinical studies available to
date in the literature are not enough supportive of a role for adaptive
immune infiltrate on the efficacy of chemotherapy treatment in CRC.
Better understanding of the molecular pathways leading to the
chemo-responsiveness may generate new strategies or new cellular
mediators able to enhance chemotherapy-driven anti-tumour activity.
Concluding statements
The evidence that CRC is a heterogeneous, multifactorial disease with
different outcomes, prognosis and/or response to treatments in histo-
logically equivalent tumours is suggestive of the complexity of cancer
behaviour along its progression. Even the most refined experimental
models of CRC available to date do not mimic the diversity of immune
infiltration among human patients. The idea that chemotherapy treat-
ment is effective only at advanced stages of disease is overlooked in
both clinical and preclinical studies relating immune cells and CRC
prognosis. Translational and clinical studies to understand whether
adaptive immune cells or other cellular players control the growth of
CRC micro-metastasis and their interactions in the setting of chemo-
therapy are warranted. Acknowledgement of the dual roles of the
immune system, from the onset of CRC along its progression, will
help design and develop consistent strategies in preclinical and clini-
cal investigation that might ultimately result in a better clinical man-
agement of patients.
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